I am pleased to join Catabasis
to help advance the company's corporate strategy as the company enters this next phase of growth," said Mr.
We are very pleased to be collaborating with PPMD for the execution of our Phase 2 trial of CAT-1004 in DMD", said Jill Milne, PhD, Catabasis
co-founder and CEO.
In October, Catabasis
announced the initiation of a Phase 1 clinical trial for its lead product candidate, CAT-1004.
chief executive officer and co-founder of Catabasis
, will present at the Oppenheimer 22nd Annual Healthcare Conference, being held Dec.
Since joining the Catabasis
management team a year ago, Michael has been instrumental in driving our clinical development program forward," said Michael Jioursek, Ph.
Using its proprietary SMART Linker technology, Catabasis
conjugates two drugs that act on different components of a disease pathway with the goal of producing new chemical entities with significantly enhanced efficacy and improved safety and tolerability profiles.
co-founder and chief scientific officer of Catabasis
Pharmaceuticals, will serve as a moderator for the discussion "Exploring the Inflammation/Diabetes Connection" at 7:30 a.
We are thrilled to add Andy Nichols to the Catabasis
team," said Michael Jirousek, Ph.
The initiation of this Phase 1 trial of CAT-1004 is a major milestone for Catabasis
and underscores our commitment to developing new treatment options for patients with inflammatory and metabolic disease," said Joanne M.
This experience will be indispensable to Catabasis
as it completes three Phase 2 trials of its lead SMART Linker conjugate CAT-2003 in hypertriglyceridemias this year, and advances additional candidates based on its SMART Linker conjugation technology in dyslipidemias and inflammatory diseases.
Pharmaceuticals, a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids and other well-characterized compounds to create dual action medicines for the treatment of inflammatory and metabolic diseases, today announced the appointment of Joanne M.
5, 2013 /PRNewswire/ -- Catabasis